SINGAPORE September 2023 : CellResearch Corporation Appoints Troels Jordansen as CEO of CellResearch Therapeutics (CRT)
- Former Glycostem executive joins CRT to lead development of cord lining stem cells base platform and pipeline
- Corlicyte® is an umbilical cord lining stem cell therapy, for patients suffering with a Diabetic Foot Ulcer (“DFU”)
- Corlisome® is an enriched supernatant derived from cord lining stem cells being developed to treat Androgenic Alopecia (AGA)
- DFU is a global health emergency that will affect close to 20% of the diabetic population in their lifetime1
- 5-year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer2
Singapore, September 2023 – CellResearch Corporation, a pioneering cellular therapy biotech company based in Singapore, is delighted to announce the appointment of Troels Jordansen as the new CEO of its therapeutics division, CellResearch Therapeutics. This strategic move underscores CellResearch Corporation’s commitment to advancing innovative cellular therapies and marks an important milestone in the company’s journey of scientific discovery and innovation.
Founded in 2002, CellResearch Corporation initially established itself as a contract research provider specializing in skin cells. However, in 2004, the company achieved a ground-breaking breakthrough by discovering that the umbilical cord lining of mammals represents a rich source of both mesenchymal and epithelial stem cells. This remarkable discovery led to the development of a family of patents and the exclusive rights to commercialize this technology in global markets.
Today, CellResearch Corporation continues to be a leader in the field of regenerative medicine. The company’s dedication to scientific excellence and innovation has resulted in numerous milestones, including the successful progression of its diabetic foot ulcer closure therapy through Phase 1 clinical trial at University of Colorado, marking a significant achievement in the field of allogeneic therapy.
Gavin Tan, CEO of CellResearch Corporation, expressed his enthusiasm for Troels Jordansen’s appointment, stating, “We are thrilled to welcome Troels to our team. His extensive experience, global network, and leadership acumen will undoubtedly enhance our capabilities in the cellular therapy sector. We believe his expertise will be instrumental in driving CellResearch Therapeutics to new heights as we continue our mission to transform regenerative medicine.”
In addition to its pioneering work in diabetic foot ulcer closure, CellResearch Therapeutics boasts a diverse and promising therapeutic pipeline at the pre-clinical stage. These pipeline projects encompass a wide range of therapeutic areas, including inflammatory diseases, cardiac muscle repair, Parkinson’s Disease, Age-related Macular Degeneration, and critical limb ischemia.
Troels Jordansen, the newly appointed CEO of CellResearch Therapeutics, will lead the charge for fundraising efforts, leveraging his extensive experience in managing projects that have raised over $300 million. Furthermore, he has set the strategic focus of the disease indications to be diabetic foot ulcers and androgenic alopecia, reinforcing the company’s commitment to addressing critical medical needs.
Notably, in October 2022, CellResearch Therapeutics presented two publications at the prestigious DFCon Conference, shedding light on the company’s significant contributions to the field of diabetic foot ulcers. These presentations showcased the company’s commitment to advancing scientific knowledge and its dedication to improving patients’ lives through innovative therapies.
Troels Jordansen shared his excitement about his new role, stating, “I am honoured to join CellResearch Corporation group of companies which has a rich history of ground-breaking discoveries and a clear commitment to pushing the boundaries of regenerative medicine.
Together, we will continue to explore and develop innovative therapies that have the potential to transform the lives of patients around the world.”
With Troels Jordansen at the helm of Cell Research Therapeutics and the continued dedication of the entire CellResearch Corporation team, the company is poised for continued success in driving the future of regenerative medicine.
Notes to Editors
About CellResearch Corporation (“CRC”)
CellResearch Corporation was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialise this technology in most major markets globally. While the closure of diabetic foot ulcers is the company’s first allogeneic therapy to make it to the end of Phase 1 clinical trial at University of Colorado, CellResearch Corporation has a broad therapeutic pipeline at the pre-clinical stage. Further therapies include inflammatory diseases, cardiac muscle repair, Parkinson’s Disease, Age-related Macular Degeneration and critical limb ischemia. In October 2022 CellResearch Corporation has had two publications presented on the subject of diabetic foot ulcer at the prestigious DFCon Conference.
CellResearch Consumer Health Pte. Ltd. is a wholly owned subsidiary of CellResearch Corporation and produces an innovative range of skincare and hair care products using cord lining stem cell media to power its products. It is home to two innovative brands. Calecim® Professional: Anti-aging skincare and Sollagen™: Diabetic Skincare both are powered by a proprietary ingredient: PTT-6™ a complex mixture of peptides and growth factors derived from cord lining stem cells.
CellResearch Corporation partner, Cordlife Asia offers parents the opportunity to bank their child’s umbilical cord tissue alongside their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue globally. As cell therapies move into the clinic, Cordlife will have the ability to expand stem cells from a banked umbilical cord for autologous and donor-related uses.
1 Yazdanpanah L, et al. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort
(ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018;2018:7631659. Published 2018 Mar 15.
doi:10.1155/2018/7631659
2 Armstrong DG, Boulton AJM, Bus S. Diabetic Foot Ulcers and their Recurrence. New England Journal of Medicine
2017: 15; 376 (24): 2367-2375.